Value-Based Agreements On The Cards For UniQure/CSL’s $3.5m Hemophilia B Gene Therapy
On Top Of Up To 30% Discounts
While Hemgenix has courted criticism since its $3.5m price tag was unveiled, a drug pricing expert has told Scrip discounts and value-based agreements could make the therapy more palatable to payers.
